EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis

EE424 Cost-Utility and Budget Impact Analyses of Tumor Necrosis Factor Inhibitor Biologics and Biosimilars Versus Rituximab in Thai Patients with Active Rheumatoid Arthritis

Saved in:
Bibliographic Details
Published in:Value in health Vol. 26; no. 12; pp. S132 - S133
Main Authors: Leelahavarong, P., Osiri, M., Koolvisoot, A., Prawjaeng, J., Budtarad, N.
Format: Journal Article
Language:English
Published: 01-12-2023
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
ISSN:1098-3015
DOI:10.1016/j.jval.2023.09.690